> Details

Filipits, Martin; Nielsen, Torsten O.; Rudas, Margaretha; Greil, Richard; Stöger, Herbert; Jakesz, Raimund; Bago-Horvath, Zsuzsanna; Dietze, Otto; Regitnig, Peter; Gruber-Rossipal, Christine; Müller-Holzner, Elisabeth; Singer, Christian F.; Mlineritsch, Brigitte; Dubsky, Peter; Bauernhofer, Thomas; Hubalek, Michael; Knauer, Michael; Trapl, Harald; Fesl, Christian; Schaper, Carl; Ferree, Sean; Liu, Shuzhen; Cowens, J. Wayne; Gnant, Michael

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
  • Contributor: Filipits, Martin; Nielsen, Torsten O.; Rudas, Margaretha; Greil, Richard; Stöger, Herbert; Jakesz, Raimund; Bago-Horvath, Zsuzsanna; Dietze, Otto; Regitnig, Peter; Gruber-Rossipal, Christine; Müller-Holzner, Elisabeth; Singer, Christian F.; Mlineritsch, Brigitte; Dubsky, Peter; Bauernhofer, Thomas; Hubalek, Michael; Knauer, Michael; Trapl, Harald; Fesl, Christian; Schaper, Carl; Ferree, Sean; Liu, Shuzhen; Cowens, J. Wayne; Gnant, Michael
  • Published: American Association for Cancer Research (AACR), 2014
  • Published in: Clinical Cancer Research, 20 (2014) 5, Seite 1298-1305
  • Language: English
  • DOI: 10.1158/1078-0432.ccr-13-1845
  • ISSN: 1078-0432; 1557-3265
  • Origination:
  • Footnote:
  • Description: AbstractPurpose: To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort of postmenopausal, endocrine-responsive breast cancer patients.Experimental Design: The PAM50 assay was performed on formalin-fixed paraffin-embedded whole-tumor sections of patients who had been enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels of the PAM50 genes were determined centrally using the nCounter Dx Analysis System. Late distant recurrence-free survival (DRFS) was analyzed using Cox models adjusted for clinical and pathologic parameters.Results: PAM50 analysis was successfully performed in 1,246 ABCSG-8 patients. PAM50 ROR score and ROR-based risk groups provided significant additional prognostic information with respect to late DRFS compared with a combined score of clinical factors alone (ROR score: ΔLRχ2 15.32, P < 0.001; ROR-based risk groups: ΔLRχ2 14.83, P < 0.001). Between years 5 and 15, we observed an absolute risk of distant recurrence of 2.4% in the low ROR-based risk group, as compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease.Conclusion: PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late distant recurrence beyond what can be achieved with established clinicopathologic risk factors. Clin Cancer Res; 20(5); 1298–305. ©2014 AACR.
  • Access State: Open Access